SCHEMBL29747565

SCHEMBL29747565

S=c1[nH]c2cc(-c3ccccc3)ccc2o1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 1.00
GAA P10253 3/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
MAPT P10636 1/20 1.00
PSMB8 P28062 7/20 0.58
ALDH1A1 P00352 4/20 0.58
PDE3B Q13370 1/20 0.45
PDE3A Q14432 1/20 0.45
KEAP1 Q14145 1/20 0.43
PGR P06401 1/20 0.41
HPGD P15428 1/20 0.41
PPARG P37231 1/20 0.41
NCOA2 Q15596 1/20 0.41
NCOA1 Q15788 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
TNKS2 Q9H2K2 1/20 0.39
FGFR1 P11362 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4699050 1.00 KDM4E (1.00) KDM4EGAAMEN1KMT2AMAPT
SCHEMBL12716526 0.91 KDM4E (0.82) KDM4EGAAMEN1KMT2AMAPT
SCHEMBL4703352 0.86 KDM4E (0.75) KDM4EGAAMEN1KMT2AMAPT
SCHEMBL17260645 0.79 PDE3B (0.71) KDM4EGAAMEN1KMT2AMAPT
SCHEMBL97140 0.74 PSMB8 (1.00) KDM4EGAAMEN1KMT2AMAPT
SCHEMBL30834681 0.74 PSMB8 (1.00) KDM4EGAAMEN1KMT2AMAPT
SCHEMBL10897160 0.73 PSMB8 (0.63) KDM4EGAAMEN1KMT2AMAPT
SCHEMBL21613695 0.72 KDM4E (0.56) KDM4EGAAMEN1KMT2AMAPT
SCHEMBL4704344 0.72 PSMB8 (0.61) KDM4EGAAMEN1KMT2AMAPT
SCHEMBL14403384 0.72 PSMB8 (0.72) KDM4EGAAMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220257583-A1 Compositions and Methods for the Treatment of Intracranial Diseases UNIV DUKE (US) 2022-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220257583-A1 Compositions and Methods for the Treatment of Intracranial Diseases S1PR1, S1PR3, S1PR2 KDM4E 4048/4885GAA 2875/4885MEN1 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.